• STAT Plus: What will it take for Gilead to break even on its $21 billion deal?

    16 days ago - By STAT

    For years, investors have pestered Gilead Sciences with the same question in myriad phrasings: When are you going to buy something big? Now, before the ink has even dried on the company's commitment to a $21 billion acquisition , they're wondering just how Gilead can justify that price.
    The deal, which gives Gilead control of the cancer drug maker Immunomedics, came at a more than 100% premium to the company's most recent stock price, making it the most expensive large acquisition in 10 years of biotech history, according to the analysts at SVB Leerink. Gilead management said it expects...
    Read more ...